Oncology · MelanomaTrial Updateclinicalmid-term

Mayo Clinic Trial on CBT for Quality of Life in Stage III-IV Melanoma Patients

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/27/2026, 12:30:48 AM

Assessment confidence: 40% · The main uncertainty is whether medium-relevance evidence fully captures sub-indication-specific dynamics.

Executive Thesis

This clinical trial is pivotal as it explores the integration of cognitive behavioral therapy into the standard care for melanoma patients, addressing a critical gap in mental health support. Successful outcomes could redefine treatment paradigms and enhance patient management strategies in oncology. Regulatory context from FDA (Verified Clinical Benefit | Cancer Accelerated Approvals) supports the near-term read. Assessment grounded in 2 ranked evidence items (0 high-relevance).

Strategic Assessment

If successful, this could lead to the integration of CBT-C into standard care for melanoma patients, impacting future treatment strategies and patient management. The strongest clinical anchor is Quality of Life in Patients Who Have Undergone Stem Cell Transplant (ClinicalTrials.gov), weak alignment to signal sub-indication and entities. In melanoma, 2 regulatory and 0 competitive items passed relevance filtering for stage III-IV melanoma patients.

Competitive Pressure

The most relevant competitive pressure comes from This trial addresses a growing need for mental health support in melanoma survivorship, potentially influencing treatment paradigms and patient care standards..

Regulatory Outlook

Regulatory risk is concentrated around Verified Clinical Benefit | Cancer Accelerated Approvals (FDA). Moderate corpus alignment. The trial's outcomes may lead to changes in clinical practice guidelines, which could necessitate updates in regulatory submissions and compliance for oncology therapies.

Key Risks

Elevated medium regulatory exposure for stage III-IV melanoma patients could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If CBT-C becomes a standard part of care, it could influence market dynamics and patient preferences, potentially affecting the competitive positioning of oncology products and services.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.
If successful, this could lead to the integration of CBT-C into standard care for melanoma patients, impacting future treatment strategies and patient management.

What Would Change This Assessment

This becomes more urgent if Monitor trial outcomes related to quality of life improvements and potential shifts in clinical practice guidelines for melanoma care.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
Outcome from Verified Clinical Benefit | Cancer Accelerated Approvals would change the regulatory/clinical read.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Verified Clinical Benefit | Cancer Accelerated Approvals
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer
MHRAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Quality of Life in Patients Who Have Undergone Stem Cell Transplant
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Clinical Trial to Evaluate the Effects of the Edge+Ease PM+AM System on Mood, Mental Clarity, Sleep Quality, and Digestive Wellbeing
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Pola-R-CHP shows promise in treating CD5-positive DLBCL, predicts patient outcomes
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Effects of a brief primary care intervention for post-traumatic stress disorder symptoms after critical illness on health-related quality of life - A secondary analysis of the PICTURE randomised contr
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Adaption of a posttraumatic stress disorder intervention for patients who use stimulants and opioids in the opioid treatment programme setting.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of sub-anesthetic doses of esketamine on immune function and postoperative negative emotions in acoustic neuroma patients: a randomized clinical trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
The role of capacitive hyperthermia as an adjunct treatment in oncology: a systematic review of randomized phase III trials.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Efficacy and safety of a novel 532-nm picosecond Nd:YAG laser for the treatment of freckles in Chinese patients: a randomized, split-face, multicenter, noninferiority trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effect of transcutaneous auricular vagus nerve stimulation on postoperative pain in patients undergoing thoracoscopic partial lung resection: a randomized, double-blind, controlled clinical trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

stage III-IV melanoma patients
oncology treatment guidelines

Commercial impact

medium

If CBT-C becomes a standard part of care, it could influence market dynamics and patient preferences, potentially affecting the competitive positioning of oncology products and services.

Regulatory impact

medium

The trial's outcomes may lead to changes in clinical practice guidelines, which could necessitate updates in regulatory submissions and compliance for oncology therapies.

What to watch

Monitor trial outcomes related to quality of life improvements and potential shifts in clinical practice guidelines for melanoma care.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.